

# Clinical relevance of metrology for drug delivery

Annemoon Timmerman

*The research leading to the results discussed in this report has received funding from the European Metrology Research Programme (EMRP). The EMRP is jointly funded by the EMRP participating countries within Euramet and the European Union.*

# Relevance of metrology for drug delivery: a clinical case

Preterm neonate: (gestational) age  
28 weeks

Patient mean blood pressure drops to  
25 mmHg, goal: 28 mmHg

Low blood pressure and frequent  
pressure changes can lead to brain  
damage

Need to increase the blood pressure



# Patient (age 28 weeks) has mean blood pressure: 25 mmHg. Goal = 28 mmHg


- Start treatment: 0.5 ml/h Dopamine infusion
- After 30 minutes, no visible effect: increase Dopamine infusion to 0.7 ml/h
- 30 minutes later: mean blood pressure is 50 mmHg  
**Too high!**
- Set Dopamine infusion lower again
- Remains high



This is exactly what we want to prevent!




# Typical multi-infusion setup



# Why is multi-infusion difficult?

Hard to administer right amount of drug

- Condition of the patient:
  - Restricted fluid intake (especially NICU)
- Some drugs are:
  - Fast acting
  - Potent (strong)
- Some drugs have a small therapeutic range:
  - Too low or too high dosage is dangerous





# Causes of dosing errors

- Accuracy of pumps only in stabilized situations
- During changes in flow rate two effects play a role:
  - ❖ **Compliance effect**
  - ❖ **Dead volume effect**
- They cause:
  - Delay in correct drug administration
  - Temporary overdosing or underdosing




# Control mechanism syringe pump infusion



- Driving mechanism:
  - Displacement of plunger by step motor
- Control mechanism
  - Change in step motor velocity
- Setpoint parameter
  - Flow rate
- Non plunger displacement induced flowrate changes are not noticed by the system
-  poor measurability
-  poor controllability



# System Mechanical Compliance effect




- Compliance: deformation of components at pressure changes
- On pressure increase fluid is stored inside parts of the system
  - Does not enter the patient
- Clinical situation: 2 syringe pumps. setpoint of 1 pump is increased
  - output of new dose of drug 1 is delayed
  - Temporary dose decrease from drug 2







# Compliance effect




# Compliance effect




# Compliance effect



# Compliance effect




# Compliance effect



# Clinical relevance compliance effect

- Compliance effects:
  - Components store fluid
  - Delay changes in flow rate
  - Acts in opposite direction to flow rate change
  - If flow rate is low compared to stored volume, the dose effect is large
- Compliance of infusion system components should be measured




A typical start up curve for an arterial line.

If flow rates  $< 0,25$  ml/h last 10 minutes, blood clotting can occur




# Dead Volume effect

- Dead Volume:
  - Volume of lines etc. **after** the mixing point



# Dead Volume effect


- The contents of Dead Volume are always flushed at the combined flow rate of the pumps:






# Dead volume effect

- Now we change the flow rate of one pump



# Dead Volume effect

- Unintended dosing during Dead Volume flushing
- Intended Flow Rate Change is delayed



# Dead volume effect

- Clinical case:
  - Female patient, 62 years of age, no history of disease, had a subarachnoid hemorrhage yesterday is operated for clipping of aneurysm
  - Blood pressure has lowered too far after induction and inserting arterial line and central venous pressure device
  - Noradrenaline therapy is started using a saline carrier flow
  - Onset of blood pressure increase has not started after 15 minutes!
  - Anesthetist increases flow rate
  - After 20 minutes blood pressure increases too much
  - Anesthetist stops noradrenaline therapy
  - Blood pressure keeps increasing: a rebleed occurs
- Dead volume effect:
  - At flow rate change volume after mixing point, having old concentration ratio
  - acts in same direction as the flow rate change
  - Clinically relevant dosing errors occur mostly at high flow rates



# Standards and regulations

- Pumps: IEC/EN 60601-2-24
  - Describes “trumpet curve”
- Syringes: ISO 7886-2 TC 84
  - Describes maximum compliance
  - Describes maximum “dead volume”



No specific regulations for low flowrate/ specific applications (Compliance might be 3x one hours dose)



No protocols describing maximum internal volume



No output measurements of entire system (pump+syringe+infusion line and catheter)



# Dosing errors: the consequences

- High flowrates, urgent acting (e.g. modifying blood pressure in a SAB clipping of aneurysm procedure):
  - Possible overdosing of Noradrenaline due to misunderstood internal volume, causing rebleeding
- Low flowrates, stabilising neonatal conditions:
  - Possible flowrate variations due to height differences of pumps: variations in cerebral blood pressure, harmful to the brain, bleeding
- Low flowrates, use of volumetric pump:
  - Cyclic variations in dose



# Conclusion

- Compliance
  - Delays flow rate change
  - Acts in opposite direction to flow rate change
  - If flow rate is low compared to stored volume, the dose effect is large
  - Clinically relevant dosing errors occur mostly at low flow rates and with fast acting drugs with a small therapeutic bandwidth
- Dead volume effect:
  - At flow rate change volume after mixing point, having old concentration ratio
  - acts in same direction as the flow rate change
  - Clinically relevant dosing errors occur mostly at high flow rates and with fast acting drugs with a small therapeutic bandwidth
- For each flow rate change: combination of Dead Volume and Compliance effects
  - Delay in intended administration change
  - Dosing errors contrary to expectations of user
  - Dosing errors in the **other** pumps as well



# Take home

- System mechanical compliance
  - should be measured, especially for low flow rate applications and for applications using fast acting drugs with a narrow therapeutic bandwidth
  - adaptation of standards for critical application should be seriously considered
- Dead volume
  - effects can cause very serious and even fatal effects, especially in high flow rate critical applications
  - Should be taken into account for establishing infusion system performance
- We still are in desperate need for innovations in infusion devices, mitigating these effects



# Reseachers



Prof. Dr. A.C.G. Egberts (Toine), Head of Pharmacy, medication management  
Dpt of Pharmacy



Prof. F van Bel (Frank), Former Head of Neonatology, perinatal neurology



Dr. P.M.A. (Petra) Lemmers, Neonatologist, perinatal neurology



Dr. A. (Agnes) van den Hoogen, RN, perinatal infections



Dr. Ir. A.M.D.E. Timmerman (Annemoon), Medical Physicist, Infusion medical physics  
Dpt of Medical Technology and Clinical Physics (MTKF)



Dr. Ir. J.E.N. Jaspers (Joris), Associate professor labour saving devices,  
Head of Innovation, MTKF Dpt



Dr. M.K. Konings (Maurits), Senior Research Physicist, inventor of medical devices  
MTKF Dpt



Ir. B. Riphagen (Brechtje), Entrepreneur, owner of Innofuse, PhD Candidate



Ir. R.A. Snijder (Roland), Biomedical Engineer, PhD Candidate

Drs R.E. Wassman (Roeland), Pharmacist, dose error reduction software for PCA  
infusion



J.H. Radermacher (Joris), graduation student in physics

M.J.J. Lardinois (Marijn), student in biomedical sciences



UMC Ut





# Infusion research in UMC Utrecht

Medical Physics and Medical Device Innovation

Pharmacy

Infusion medical physics

Medication management and infusion



Medical device development  
and valorisation



Physics and mathematics

Entrepreneurship

Neonatology



Modeling  
and measuring

Development  
and market introduction

InniOfuse



Perinatal  
Infections

Perinatal Neurology



UMC Utrecht

Biomedical sciences – business management

# Questions



# Disclaimer

Part of this research was funded in the EMRP project Metrology for drug delivery. The EMRP is jointly funded by the EMRP participating countries within EURAMET and the European Union.

